GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Book Value per Share

JW (Cayman) Therapeutics Co (HKSE:02126) Book Value per Share : HK$3.84 (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co Book Value per Share?

JW (Cayman) Therapeutics Co's book value per share for the quarter that ended in Jun. 2024 was HK$3.84.

During the past 12 months, JW (Cayman) Therapeutics Co's average Book Value Per Share Growth Rate was -32.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -24.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of JW (Cayman) Therapeutics Co was -24.80% per year. The lowest was -24.80% per year. And the median was -24.80% per year.

JW (Cayman) Therapeutics Co's current price is HK$1.37. Its book value per share for the quarter that ended in Jun. 2024 was HK$3.84. Hence, today's PB Ratio of JW (Cayman) Therapeutics Co is 0.31.

During the past 6 years, the highest P/B Ratio of JW (Cayman) Therapeutics Co was 1.60. The lowest was 0.28. And the median was 0.49.


JW (Cayman) Therapeutics Co Book Value per Share Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Book Value per Share Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial -2.79 10.48 8.38 6.40 4.47

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.43 6.40 5.69 4.47 3.84

Competitive Comparison of JW (Cayman) Therapeutics Co's Book Value per Share

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JW (Cayman) Therapeutics Co's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's PB Ratio falls into.



JW (Cayman) Therapeutics Co Book Value per Share Calculation

JW (Cayman) Therapeutics Co's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1,841.7-0.0)/412.4
=4.47

JW (Cayman) Therapeutics Co's Book Value Per Share for the quarter that ended in Jun. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1,595.4-0.0)/415.1
=3.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


JW (Cayman) Therapeutics Co  (HKSE:02126) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


JW (Cayman) Therapeutics Co Book Value per Share Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


JW (Cayman) Therapeutics Co Business Description

Traded in Other Exchanges
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Executives
Li Dan 2202 Interest of your spouse
Li Yiping James 2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd. 2501 Other
Bristol-myers Squibb Company 2201 Interest of corporation controlled by you
Celgene Corporation 2201 Interest of corporation controlled by you
Juno Therapeutics, Inc. 2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd. 2501 Other

JW (Cayman) Therapeutics Co Headlines

No Headlines